H3K18 Lactylation-Mediated NOD2 Expression Promotes Pyroptosis in Bilirubin Encephalopathy: Mechanistic Insights and Methodological Advances

Study Background and Research Question

Neonatal hyperbilirubinemia, affecting up to 80% of preterm and 60% of term neonates, remains a significant clinical concern due to its potential to cause bilirubin encephalopathy (BE) and chronic neurological deficits such as kernicterus. Despite preventive advances, BE persists, particularly in low- and middle-income countries, with neuroinflammation identified as a central pathogenic feature. Astrocytes, the most abundant glial cells in the brain, have been implicated in amplifying neuroinflammatory responses to elevated unconjugated bilirubin (UCB). However, the molecular mechanisms linking metabolic adaptation, epigenetic regulation, and astrocyte pyroptosis in BE remain poorly defined.

Key Innovation from the Reference Study

Li et al. (2025) provide crucial mechanistic insight by identifying histone H3K18 lactylation (H3K18la) as a driver of nucleotide-binding oligomerization domain 2 (NOD2) transcription in astrocytes exposed to bilirubin. This study is among the first to connect glycolysis-derived histone lactylation to the regulation of inflammatory cell death (pyroptosis) in glial cells, establishing the H3K18la/NOD2 axis as a pivotal mediator of neuroinflammation in BE. The work also positions metabolic-epigenetic crosstalk as a potential therapeutic target in neonatal neurotoxicity.

Methods and Experimental Design Insights

The authors utilized both in vitro and in vivo models to dissect the molecular underpinnings of astrocyte pyroptosis under bilirubin stress. Primary rat astrocytes were treated with UCB to model BE-related injury, while rat hippocampal tissue provided in vivo validation. Key methodological highlights include:

• Assessment of H3K18 lactylation dynamics in astrocytes and hippocampal tissue using immunoblotting and immunofluorescence after UCB exposure.
• Pharmacological inhibition of glycolysis to probe the metabolic dependency of H3K18la induction and subsequent pyroptotic signaling.
• CUT&Tag (Cleavage Under Targets and Tagmentation) and RNA-seq to map H3K18la chromatin occupancy and its effect on gene transcription, focusing on NOD2 promoter enrichment.
• Evaluation of pyroptosis by measuring cell death markers, membrane permeabilization, and release of pro-inflammatory cytokines (e.g., IL-1β, TNF-α).
• Signaling pathway interrogation for MAPK and NF-κB downstream of NOD2 activation.

This rigorous, multi-layered approach ensured robust mechanistic conclusions and provided a framework for future studies into metabolic-epigenetic regulation in glial cells.

Core Findings and Why They Matter

The study's central findings can be summarized as follows:

• H3K18 lactylation is upregulated in both UCB-stimulated astrocytes and BE rat hippocampus, mirroring increased glycolytic activity and lactate production under inflammatory conditions.
• Pharmacological blockade of glycolysis reduces H3K18la, NOD2 expression, and markers of pyroptosis, indicating that glycolytic flux is essential for this epigenetic modification and its downstream effects.
• Genome-wide profiling (CUT&Tag and RNA-seq) confirms H3K18la enrichment at the NOD2 promoter, causally linking this histone mark to NOD2 transcriptional upregulation.
• Elevated NOD2 expression potentiates MAPK and NF-κB signaling, exacerbating pro-inflammatory cytokine release and pyroptotic cell death in astrocytes, which amplifies neuroinflammation in BE.

These results offer the first direct evidence that H3K18la-driven NOD2 expression is a key mechanism by which metabolic stress translates into inflammatory cell death in astrocytes. The implication is profound: targeting the glycolysis–histone lactylation–NOD2 axis may represent a novel therapeutic strategy to prevent or mitigate BE-related neuropathology.

Comparison with Existing Internal Articles

The mechanistic advances reported by Li et al. (2025) complement and extend previous discussions on the utility of Polyethylenimine Linear (PEI), MW 40,000 in molecular neurobiology research. For example, one internal resource highlights the role of PEI MW 40,000 as a highly efficient, serum-compatible DNA transfection reagent suitable for transient gene expression studies in neuroepigenetic contexts. Integrating these approaches enables researchers to manipulate gene expression (e.g., NOD2 or glycolytic enzymes) to validate mechanistic hypotheses in vitro.

Additionally, application-focused guidance underscores PEI MW 40,000's scalability and compatibility with workflow formats ranging from 96-well plates to bioreactors. This versatility is particularly valuable for studies that require high-throughput validation of multiple candidate targets or the generation of recombinant astrocyte lines for epigenetic research.

Collectively, these internal articles provide practical insight into optimizing transfection protocols and troubleshooting, reinforcing the critical role of PEI-based reagents in advancing mechanistic neuroinflammation research.

Limitations and Transferability

While the study by Li et al. offers compelling evidence for the H3K18la/NOD2 axis in astrocyte-mediated neuroinflammation, certain limitations should be considered for translational and methodological generalization:

• The primary cellular models are rat astrocytes, and while many metabolic-epigenetic pathways are conserved, extrapolation to human neurobiology requires additional validation.
• The complex interplay between astrocytes, microglia, and neurons in vivo is not fully recapitulated in isolated cell cultures. Thus, in vivo studies remain critical for evaluating therapeutic interventions.
• Pharmacological inhibitors of glycolysis and epigenetic marks may have off-target effects, necessitating careful experimental controls and genetic validation (e.g., CRISPR/Cas9-mediated gene editing).

The transferability of these findings to other models of neuroinflammation or injury, as well as to different glial or neuronal subtypes, should be systematically tested using robust gene delivery and functional genomics platforms.

Protocol Parameters

• Astrocyte culture and UCB stimulation: Primary rat astrocytes exposed to 10–20 μM unconjugated bilirubin for 24–48 hours to induce injury and model BE conditions.
• Glycolytic inhibition: 2-deoxyglucose (2-DG) or similar glycolytic inhibitor applied 1–2 hours prior to UCB challenge to assess dependency of H3K18la induction.
• Transfection for mechanistic validation: Use of Polyethylenimine Linear (PEI), MW 40,000 to deliver plasmids or siRNAs targeting NOD2 or glycolytic regulators, in serum-containing conditions, typically at a PEI:DNA mass ratio of 3:1, with incubation for 4–6 hours before media change.
• Pyroptosis and cytokine assays: Quantification of LDH release, membrane permeability (e.g., propidium iodide uptake), and ELISA for IL-1β and TNF-α, 24–48 hours post-stimulation.
• Chromatin profiling: CUT&Tag performed on 50,000–100,000 astrocytes per sample, using validated anti-H3K18la antibodies, followed by sequencing and analysis of NOD2 promoter occupancy.

Research Support Resources

For researchers seeking to replicate or extend these mechanistic studies, reliable gene delivery is essential. Polyethylenimine Linear (PEI), MW 40,000 (SKU K1029) is a widely used DNA transfection reagent for in vitro studies, supporting transient gene expression and recombinant protein production across cell lines, including astrocytes and HEK-293. Its high efficiency in serum-containing media and scalability from microplates to bioreactors make it suitable for both exploratory and high-throughput workflows, as outlined in the internal article.

By combining robust epigenetic and metabolic analyses with reliable transfection methodologies, researchers can further dissect the regulatory networks that underpin neuroinflammatory disorders such as BE, and evaluate novel intervention strategies targeting the H3K18la/NOD2 pathway.